Stryker
Preço: 312.20Empresa e modelo de negócios
Stryker Corporation is a leading medical technology company that develops and manufactures a range of products in the healthcare sector. Its core offerings include surgical equipment, orthopedic implants, neurotechnology, and spine products. Major business segments consist of Orthopedics, MedSurg, and Neurotechnology & Spine. The primary revenue sources are derived from sales of surgical instruments, implants, and related services.
Perfil de investimento
The investment profile of Stryker is more aligned with value investors, given its current dividend yield and established market presence. However, recent revenue declines and earnings surprises may indicate challenges in growth potential. The stock may appeal to those seeking stability rather than aggressive growth.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- 8.73 OK
- Receita QoQ — crescimento da receita trimestre contra trimestre
- -16.1% ↓
- Surpresa de EPS
- -12.8% pior que o esperado
- Volatilidade 20d
- 1.8% estável
- Dividend yield
- 1.4% moderado última data ex-dividendo: 2026-06-30
Impacto da previsão
negativoAcompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-05-10 02:45 | Manter | Vender | scenario_deterioration |
| 2026-05-08 15:19 | — | Manter | Weak fundamentals and negative momentum indicate high risk. |
| 2026-05-08 06:38 | Manter | Manter | Компания Stryker демонстрирует значительное снижение выручки и негативные тренды на фондовом рынке, что указывает на высокие риски для инвесторов. Учитывая текущие показатели и негативные прогнозы, рекомендуется рассмотр |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-06-05 09:16 | Leerink Partners | Preço-alvo reduzido | — → 407 | 301.21 |
| 2026-05-04 13:39 | Truist Financial | Preço-alvo reduzido | 380 → 330 | 293.44 |
| 2026-05-04 09:27 | Barclays | Preço-alvo reduzido | 469 → 394 | 294.73 |
Nada ainda